Amicus Therapeutics (FOLD)
(Delayed Data from NSDQ)
$10.05 USD
-0.22 (-2.14%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $10.06 +0.01 (0.10%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth F Momentum D VGM
Brokerage Reports
0 items in cart
Amicus Therapeutics, Inc. [FOLD]
Reports for Purchase
Showing records 141 - 160 ( 172 total )
Company: Amicus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
September 2012 Potential Catalysts & Milestones - Monthly Update
Provider: WEDBUSH SECURITIES INC.
Company: Amicus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of September 2, 2012
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Amicus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q2:12 EPS, Key Phase III Monotherapy Migalastat Data Now in Q4:12 to Accommodate FDA, Reiterate NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Amicus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of August
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Amicus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of July 29
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Amicus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Lowering Price Target,Updating and Correcting Financial Model After Restructured Partnership with GSK, Reiterate NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Amicus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Restructured GSK Partnership and Equity Investment Give Amicus US Commercial Rights, Reiterate NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Amicus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
July 2012 Potential Catalysts & Milestones - Monthly Update
Provider: WEDBUSH SECURITIES INC.
Company: Amicus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Amicus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Amicus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
June 2012 Potential Catalysts & Milestones - Monthly Update
Provider: WEDBUSH SECURITIES INC.
Company: Amicus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of June 3
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Amicus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q1:12 EPS, Key Phase II and Phase III Migalastat Data Likely in Q3:12, Reiterate NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Amicus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q4:11 Earnings a Non-Event, Data Presented at Rare Disease Conference, Reiterate NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Amicus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Semiconductor Industry Association (SIA) December Data: Revenue Increases M/M
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Amicus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
February 2012 Potential Catalysts & Milestones - Monthly Update
Provider: WEDBUSH SECURITIES INC.
Company: Amicus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of January 29
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Amicus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of January 22
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Amicus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Amicus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Initial Look at Phase II Co-Administration "013" Study Data is Positive - More Details Early February
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G